Tagged with Pharma

GSK In a pharmaceutical environment faced with stiffening regulatory regimes, and where mergers and acquisitions become more commonplace, GSK’s diversifications and growth model have long come into question. Historically, Big Pharma would work as a one-stop-shop for medicine solutions covering all therapeutic areas, and over the years, companies opened up new…

China One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates to ‘Long Life’) in Northeast China, admitted to having falsified records for over 250,000 substandard vaccines for DPT (diphtheria, pertussis,…

Spain Angel Fernandez, president and managing director of MSD Spain and Portugal, covers the company´s current pipeline and portfolio strategy. He also explains how the company collaborate with a wide variety of stakeholders.   What is the history of MSD in the Spanish market? Overall, MSD is a company with 127…

Cyprus   Jacqueline Anastassiades has been involved in the development of the Cypriot healthcare sector for more than 10 years as the Managing Director of MSD. With the upcoming healthcare reforms, she brings her expert insights into the key requirements the Cyprus national health system should validate as well as the…

UK Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric one-stop-shop by deciding on smart investments, and why quality will always remain the key differentiation factor for a CDMO. In…

UK Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential in driving forward early stage discovery. Louise Houson, Managing Director for the UK and Ireland explains the reasons for that…

UK As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back on the company’s internationalisation path. He further highlights the extremely collaborative approach Takeda engages in with NICE and gives tips…

Spain Timmo Andersen, general manager of Boehringer Ingelheim in Spain, explains how the affiliate has managed to achieve market-leading growth rates, the challenges and opportunities of the Spanish pharma market, and why BI is investing heavily in a new facility in Spain.   Boehringer Ingelheim in Spain grew an impressive 9…

Portugal Filipe Novais leads the Portuguese affiliate for Astellas during an exciting time for the company globally. With a new global CEO, Astellas is aiming to be at the forefront of healthcare changes to turn innovative science into value for patients. Novais has a lot on his plate both to achieve…

Pharma The last few years have witnessed the advent of a highly disruptive business model within the heart of the pharma world that fundamentally reconsiders the manner in which R&D is conducted and, as such, we have seen the rise (and sometimes fall) of a new breed of companies that some…

Portugal The top 20 pharma companies in Portugal ranked by sales and market share for the year leading up to March 2018. MSD leads the way with EUR 148 million in sales and a 5.4 percent market share, followed by Mylan and Bayer.

Novartis In the latest in a wave of Big Pharma companies retreating from the field of antibiotics, Novartis has decided to drop its antibacterial and antiviral early-stage research programs, laying off 140 staff in the US. This comes at a time when antibiotic-resistant strains of bacteria – so-called ‘superbugs’ – are…